"Microdosing" semaglutide is a term that has leaked out of the GLP-1 compounding and research-use scene to describe any ongoing weekly dose below the standard label starting dose of 0.25 mg. There is no formal clinical definition. The research question is simple: do sub-label doses actually move weight, appetite, or glucose? The honest answer, pulled from the dose-finding trials and the STEP program, is yes — partially — but at a cost in time to effect.
Key Takeaways
- No clinical definition exists. "Microdosing" in practice means weekly semaglutide at 0.05–0.20 mg, below the 0.25 mg label starter.
- Phase 2 dose-finding data support partial effects below 0.25 mg. Appetite suppression and modest weight loss are present at doses as low as 0.05 mg weekly, though attenuated.
- Tolerability improves roughly in proportion to the dose cut. Nausea rates track with plasma exposure; microdosing can be a tolerability bridge, not a long-term plateau strategy.
- Time-to-effect is longer. At 0.1 mg weekly, meaningful weight loss typically takes 8–12 weeks instead of 4–6.
- The STEP titration schedule is the labelled anchor. Microdosing is a deviation from it, not an alternative label.
- Clinical oversight matters. Microdosing is almost always done through compounding pharmacies or research-use channels; standard-label Ozempic pens cannot easily deliver below 0.25 mg.
What microdosing actually means
In the semaglutide context, microdosing is informal shorthand for a weekly dose below the 0.25 mg standard introductory dose used in both the T2D program (SUSTAIN) and the obesity program (STEP). In practice, user-reported microdoses cluster in the 0.05–0.20 mg weekly range, delivered using compounded semaglutide drawn into a 1 mL insulin syringe where fractional unit marks make small volumes measurable.
Microdosing is distinct from the slow label titration (0.25 mg × 4 weeks → 0.5 mg × 4 weeks → 1.0 mg → up to 2.4 mg). It is a below-label dose maintained for several weeks or months — not just the first month of an escalation.
Does microdosing semaglutide actually work?
Semaglutide is a continuous dose-response drug. The STEP and SUSTAIN programs show weight loss scales roughly linearly from 0.25 mg to 2.4 mg weekly. Dose-finding studies that preceded those programs tested doses as low as 0.05 mg and found the following pattern:
| Weekly dose | Expected 24-wk weight loss | Approx. nausea rate | Research anchor |
|---|---|---|---|
| 0.05 mg (microdose) | ~2–3% | ~10–15% | Phase 2 dose-ranging |
| 0.10 mg (microdose) | ~3–5% | ~15–20% | Phase 2 dose-ranging |
| 0.25 mg (label starter) | ~5–7% | ~20–25% | STEP-1 month 1 |
| 1.0 mg | ~10–12% | ~35% | SUSTAIN maintenance |
| 2.4 mg (label max) | ~15–17% | ~44% | STEP-1 68-week endpoint |
Numbers above are approximate magnitudes drawn from the Phase 2 dose-finding program and the Phase 3 trials; they should be read directionally, not as prescriptions. The honest reading is that microdoses do produce measurable but attenuated effects — weight loss is roughly a quarter of what the top label dose delivers, and tolerability is substantially better.
A practical microdosing protocol
Research-context microdosing protocols generally start low and escalate even more gradually than the label. One commonly cited pattern:
| Weeks | Weekly dose | Goal |
|---|---|---|
| 1–4 | 0.05 mg | Assess GI tolerance at near-threshold exposure |
| 5–8 | 0.10 mg | Begin appetite-suppression plateau |
| 9–12 | 0.15 mg | Match early STEP titration profile |
| 13+ | 0.20–0.25 mg | Transition to label starter if tolerated |
Measured on an insulin syringe (U-100 scale, where 100 units = 1 mL), these microdoses translate to roughly 5–20 units of a 2.5 mg/mL compounded concentration. The exact volume depends entirely on how the compounding pharmacy diluted the vial — a dose chart from the pharmacy is non-negotiable.
When microdosing makes sense
Four research-context scenarios where microdosing has a plausible rationale:
- Severe nausea on 0.25 mg. Dropping back to 0.10 mg for 4 weeks then re-escalating is cleaner than discontinuing.
- Weight maintenance after reaching goal. Patients who have hit their target on 1.0–2.4 mg sometimes maintain weight on 0.25–0.5 mg; microdosing is the next step below that.
- Glucose nudging in prediabetes. Small, label-off doses may be enough to improve HbA1c without the GI burden of therapeutic doses.
- Supply constraints. During the 2022–2024 semaglutide shortage, compounded microdoses extended available drug across more patients.
What microdosing does not do
Microdosing is not a workaround for the Phase 3 dose-response curve. Patients expecting label-dose weight loss on microdoses are generally disappointed. The STEP-1 15% average weight loss required 2.4 mg weekly for 68 weeks. No published data suggest microdoses can produce that magnitude of loss on an extended timeline.
Microdosing also does not meaningfully reduce cardiovascular benefit timelines (which require years, not weeks) or the specific black-box warnings on the class (thyroid C-cell signal, pancreatitis watch). Dose does not change category of risk.
Risks and limits
Three limitations deserve emphasis:
- Not label-sanctioned. Microdosing semaglutide below 0.25 mg weekly is off-label. Ozempic pens cannot deliver below 0.25 mg; compounded vials and insulin syringes are the practical route, which introduces compounding pharmacy variability.
- Measurement error. At 0.05 mg weekly, a 2-unit insulin syringe error is a 40% dosing error. Precision matters.
- Compounding regulatory flux. The FDA removed semaglutide from the shortage list in 2024–2025 and has been tightening 503A/503B compounding of GLP-1s. Access to compounded semaglutide is not guaranteed in the mid-2026 to 2027 window.
Conclusion
Semaglutide microdosing is a research-context tool, not a shortcut. It delivers attenuated but real effects on appetite and weight at a quarter to half the magnitude of label doses, with proportionally better GI tolerability. It makes sense as a tolerability bridge, a maintenance strategy after reaching goal, or a prediabetes glucose nudge — but it is not a substitute for Phase 3 titration if the goal is clinically meaningful weight loss. Any protocol below the 0.25 mg starter is off-label, depends on compounded supply, and should be run under clinician oversight.
Frequently Asked Questions
What is a semaglutide microdose?
Any weekly dose below the label starter of 0.25 mg. In practice this is usually 0.05–0.20 mg weekly.
Does microdosing semaglutide help with weight loss?
Yes, but less and slower than label doses. Expect 2–5% body weight loss over 24 weeks at microdoses, compared to 15–17% at the 2.4 mg Phase 3 maximum.
Is semaglutide microdosing FDA-approved?
No. Doses below 0.25 mg weekly are off-label and are typically delivered through compounded pharmacies rather than Ozempic or Wegovy pens.
How do you measure a 0.1 mg semaglutide dose?
On a U-100 insulin syringe, drawn from a compounded vial at a known concentration. The pharmacy should supply a dose chart; without one, measurement error is high.
Can microdosing semaglutide help nausea?
Yes. Dropping back to a microdose for 2–4 weeks and re-escalating is a well-tolerated approach when 0.25 mg produces severe GI side effects.
How long before microdosing semaglutide shows weight loss?
Typically 8–12 weeks, compared to 4–6 weeks at label doses.
Primary sources:
- Clinical pharmacology of semaglutide — Clinical Pharmacokinetics 2019
- STEP-1: Semaglutide 2.4 mg in obesity (NEJM 2021)
- Semaglutide Phase 2 dose-finding — Lancet 2017
- FDA information on semaglutide compounding
- Ozempic prescribing information
Research disclaimer: This article is a research review intended for educational use only. It is not medical advice. Semaglutide microdosing (weekly doses below 0.25 mg) is off-label; discuss any below-label protocol with a qualified clinician. Compounded semaglutide is not FDA-approved and quality varies between compounding pharmacies.
Sources & Further Reading
Peer-reviewed clinical trial data and research publications underpinning this article. See our full research library.
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384:989–1002. Phase 3 RCT
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine, 389:2221–2232. Phase 3 RCT
